Last week, the Polaris Group announced positive results of its Phase 2/3 clinical trial evaluating the effectiveness of an arginine degrading enzyme agent called ADI-PEG 20.…
1717 K Street NW, Suite 900
Washington, DC 20006-5349
(877) 363-6376
HELPLINE
